Circulating desmosine levels do not predict emphysema progression but are associated with cardiovascular risk and mortality in COPD

Roberto A. Rabinovich, Bruce E. Miller, Karolina Wrobel, Kareshma Ranjit, Michelle C. Williams, Ellen Drost, Lisa D. Edwards, David A. Lomas, Stephen I. Rennard, Alvar Agustí, Ruth Tal-Singer, Jørgen Vestbo, Emiel F.M. Wouters, Michelle John, Edwin J.R. Van Beek, John T. Murchison, Charlotte E. Bolton, William Macnee, Jeffrey T.J. Huang

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Elastin degradation is a key feature of emphysema and may have a role in the pathogenesis of atherosclerosis associated with chronic obstructive pulmonary disease (COPD). Circulating desmosine is a specific biomarker of elastin degradation. We investigated the association between plasma desmosine (pDES) and emphysema severity/progression, coronary artery calcium score (CACS) and mortality. pDES was measured in 1177 COPD patients and 110 healthy control subjects from two independent cohorts. Emphysema was assessed on chest computed tomography scans. Aortic arterial stiffness was measured as the aortic-femoral pulse wave velocity. pDES was elevated in patients with cardiovascular disease (p<0.005) and correlated with age (rho=0.39, p<0.0005), CACS (rho=0.19, p<0.0005) modified Medical Research Council dyspnoea score (rho=0.15, p<0.0005), 6-min walking distance (rho=-0.17, p<0.0005) and body mass index, airflow obstruction, dyspnoea, exercise capacity index (rho=0.10, p<0.01), but not with emphysema, emphysema progression or forced expiratory volume in 1 s decline. pDES predicted all-cause mortality independently of several confounding factors (p<0.005). In an independent cohort of 186 patients with COPD and 110 control subjects, pDES levels were higher in COPD patients with cardiovascular disease and correlated with arterial stiffness ( p<0.05). In COPD, excess elastin degradation relates to cardiovascular comorbidities, atherosclerosis, arterial stiffness, systemic inflammation and mortality, but not to emphysema or emphysema progression. pDES is a good biomarker of cardiovascular risk and mortality in COPD.

Original languageEnglish (US)
Pages (from-to)1365-1373
Number of pages9
JournalEuropean Respiratory Journal
Volume47
Issue number5
DOIs
StatePublished - May 1 2016

Fingerprint

Desmosine
Emphysema
Chronic Obstructive Pulmonary Disease
Vascular Stiffness
Mortality
Elastin
Dyspnea
Atherosclerosis
Coronary Vessels
Cardiovascular Diseases
Biomarkers
Calcium
Pulse Wave Analysis
Forced Expiratory Volume
Thigh
Walking
Biomedical Research
Comorbidity
Healthy Volunteers
Body Mass Index

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Rabinovich, R. A., Miller, B. E., Wrobel, K., Ranjit, K., Williams, M. C., Drost, E., ... Huang, J. T. J. (2016). Circulating desmosine levels do not predict emphysema progression but are associated with cardiovascular risk and mortality in COPD. European Respiratory Journal, 47(5), 1365-1373. https://doi.org/10.1183/13993003.01824-2015

Circulating desmosine levels do not predict emphysema progression but are associated with cardiovascular risk and mortality in COPD. / Rabinovich, Roberto A.; Miller, Bruce E.; Wrobel, Karolina; Ranjit, Kareshma; Williams, Michelle C.; Drost, Ellen; Edwards, Lisa D.; Lomas, David A.; Rennard, Stephen I.; Agustí, Alvar; Tal-Singer, Ruth; Vestbo, Jørgen; Wouters, Emiel F.M.; John, Michelle; Van Beek, Edwin J.R.; Murchison, John T.; Bolton, Charlotte E.; Macnee, William; Huang, Jeffrey T.J.

In: European Respiratory Journal, Vol. 47, No. 5, 01.05.2016, p. 1365-1373.

Research output: Contribution to journalArticle

Rabinovich, RA, Miller, BE, Wrobel, K, Ranjit, K, Williams, MC, Drost, E, Edwards, LD, Lomas, DA, Rennard, SI, Agustí, A, Tal-Singer, R, Vestbo, J, Wouters, EFM, John, M, Van Beek, EJR, Murchison, JT, Bolton, CE, Macnee, W & Huang, JTJ 2016, 'Circulating desmosine levels do not predict emphysema progression but are associated with cardiovascular risk and mortality in COPD', European Respiratory Journal, vol. 47, no. 5, pp. 1365-1373. https://doi.org/10.1183/13993003.01824-2015
Rabinovich, Roberto A. ; Miller, Bruce E. ; Wrobel, Karolina ; Ranjit, Kareshma ; Williams, Michelle C. ; Drost, Ellen ; Edwards, Lisa D. ; Lomas, David A. ; Rennard, Stephen I. ; Agustí, Alvar ; Tal-Singer, Ruth ; Vestbo, Jørgen ; Wouters, Emiel F.M. ; John, Michelle ; Van Beek, Edwin J.R. ; Murchison, John T. ; Bolton, Charlotte E. ; Macnee, William ; Huang, Jeffrey T.J. / Circulating desmosine levels do not predict emphysema progression but are associated with cardiovascular risk and mortality in COPD. In: European Respiratory Journal. 2016 ; Vol. 47, No. 5. pp. 1365-1373.
@article{e6a451cc68da47e0afbcba7a9cf9de4d,
title = "Circulating desmosine levels do not predict emphysema progression but are associated with cardiovascular risk and mortality in COPD",
abstract = "Elastin degradation is a key feature of emphysema and may have a role in the pathogenesis of atherosclerosis associated with chronic obstructive pulmonary disease (COPD). Circulating desmosine is a specific biomarker of elastin degradation. We investigated the association between plasma desmosine (pDES) and emphysema severity/progression, coronary artery calcium score (CACS) and mortality. pDES was measured in 1177 COPD patients and 110 healthy control subjects from two independent cohorts. Emphysema was assessed on chest computed tomography scans. Aortic arterial stiffness was measured as the aortic-femoral pulse wave velocity. pDES was elevated in patients with cardiovascular disease (p<0.005) and correlated with age (rho=0.39, p<0.0005), CACS (rho=0.19, p<0.0005) modified Medical Research Council dyspnoea score (rho=0.15, p<0.0005), 6-min walking distance (rho=-0.17, p<0.0005) and body mass index, airflow obstruction, dyspnoea, exercise capacity index (rho=0.10, p<0.01), but not with emphysema, emphysema progression or forced expiratory volume in 1 s decline. pDES predicted all-cause mortality independently of several confounding factors (p<0.005). In an independent cohort of 186 patients with COPD and 110 control subjects, pDES levels were higher in COPD patients with cardiovascular disease and correlated with arterial stiffness ( p<0.05). In COPD, excess elastin degradation relates to cardiovascular comorbidities, atherosclerosis, arterial stiffness, systemic inflammation and mortality, but not to emphysema or emphysema progression. pDES is a good biomarker of cardiovascular risk and mortality in COPD.",
author = "Rabinovich, {Roberto A.} and Miller, {Bruce E.} and Karolina Wrobel and Kareshma Ranjit and Williams, {Michelle C.} and Ellen Drost and Edwards, {Lisa D.} and Lomas, {David A.} and Rennard, {Stephen I.} and Alvar Agust{\'i} and Ruth Tal-Singer and J{\o}rgen Vestbo and Wouters, {Emiel F.M.} and Michelle John and {Van Beek}, {Edwin J.R.} and Murchison, {John T.} and Bolton, {Charlotte E.} and William Macnee and Huang, {Jeffrey T.J.}",
year = "2016",
month = "5",
day = "1",
doi = "10.1183/13993003.01824-2015",
language = "English (US)",
volume = "47",
pages = "1365--1373",
journal = "European Respiratory Journal",
issn = "0903-1936",
publisher = "European Respiratory Society",
number = "5",

}

TY - JOUR

T1 - Circulating desmosine levels do not predict emphysema progression but are associated with cardiovascular risk and mortality in COPD

AU - Rabinovich, Roberto A.

AU - Miller, Bruce E.

AU - Wrobel, Karolina

AU - Ranjit, Kareshma

AU - Williams, Michelle C.

AU - Drost, Ellen

AU - Edwards, Lisa D.

AU - Lomas, David A.

AU - Rennard, Stephen I.

AU - Agustí, Alvar

AU - Tal-Singer, Ruth

AU - Vestbo, Jørgen

AU - Wouters, Emiel F.M.

AU - John, Michelle

AU - Van Beek, Edwin J.R.

AU - Murchison, John T.

AU - Bolton, Charlotte E.

AU - Macnee, William

AU - Huang, Jeffrey T.J.

PY - 2016/5/1

Y1 - 2016/5/1

N2 - Elastin degradation is a key feature of emphysema and may have a role in the pathogenesis of atherosclerosis associated with chronic obstructive pulmonary disease (COPD). Circulating desmosine is a specific biomarker of elastin degradation. We investigated the association between plasma desmosine (pDES) and emphysema severity/progression, coronary artery calcium score (CACS) and mortality. pDES was measured in 1177 COPD patients and 110 healthy control subjects from two independent cohorts. Emphysema was assessed on chest computed tomography scans. Aortic arterial stiffness was measured as the aortic-femoral pulse wave velocity. pDES was elevated in patients with cardiovascular disease (p<0.005) and correlated with age (rho=0.39, p<0.0005), CACS (rho=0.19, p<0.0005) modified Medical Research Council dyspnoea score (rho=0.15, p<0.0005), 6-min walking distance (rho=-0.17, p<0.0005) and body mass index, airflow obstruction, dyspnoea, exercise capacity index (rho=0.10, p<0.01), but not with emphysema, emphysema progression or forced expiratory volume in 1 s decline. pDES predicted all-cause mortality independently of several confounding factors (p<0.005). In an independent cohort of 186 patients with COPD and 110 control subjects, pDES levels were higher in COPD patients with cardiovascular disease and correlated with arterial stiffness ( p<0.05). In COPD, excess elastin degradation relates to cardiovascular comorbidities, atherosclerosis, arterial stiffness, systemic inflammation and mortality, but not to emphysema or emphysema progression. pDES is a good biomarker of cardiovascular risk and mortality in COPD.

AB - Elastin degradation is a key feature of emphysema and may have a role in the pathogenesis of atherosclerosis associated with chronic obstructive pulmonary disease (COPD). Circulating desmosine is a specific biomarker of elastin degradation. We investigated the association between plasma desmosine (pDES) and emphysema severity/progression, coronary artery calcium score (CACS) and mortality. pDES was measured in 1177 COPD patients and 110 healthy control subjects from two independent cohorts. Emphysema was assessed on chest computed tomography scans. Aortic arterial stiffness was measured as the aortic-femoral pulse wave velocity. pDES was elevated in patients with cardiovascular disease (p<0.005) and correlated with age (rho=0.39, p<0.0005), CACS (rho=0.19, p<0.0005) modified Medical Research Council dyspnoea score (rho=0.15, p<0.0005), 6-min walking distance (rho=-0.17, p<0.0005) and body mass index, airflow obstruction, dyspnoea, exercise capacity index (rho=0.10, p<0.01), but not with emphysema, emphysema progression or forced expiratory volume in 1 s decline. pDES predicted all-cause mortality independently of several confounding factors (p<0.005). In an independent cohort of 186 patients with COPD and 110 control subjects, pDES levels were higher in COPD patients with cardiovascular disease and correlated with arterial stiffness ( p<0.05). In COPD, excess elastin degradation relates to cardiovascular comorbidities, atherosclerosis, arterial stiffness, systemic inflammation and mortality, but not to emphysema or emphysema progression. pDES is a good biomarker of cardiovascular risk and mortality in COPD.

UR - http://www.scopus.com/inward/record.url?scp=84969785019&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84969785019&partnerID=8YFLogxK

U2 - 10.1183/13993003.01824-2015

DO - 10.1183/13993003.01824-2015

M3 - Article

C2 - 27009168

AN - SCOPUS:84969785019

VL - 47

SP - 1365

EP - 1373

JO - European Respiratory Journal

JF - European Respiratory Journal

SN - 0903-1936

IS - 5

ER -